Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

17%(1 trials)

Phase Distribution

Ph not_applicable

10%

Ph phase_3

30%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 3Large-scale testing

3(50.0%)

Phase 4Post-market surveillance

2(33.3%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Terminated(2)

Other(1)

Detailed Status

Completed6

Withdrawn2

Not yet recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 33 (50.0%)

Phase 42 (33.3%)

N/A1 (16.7%)

Trials by Status

completed660%

withdrawn220%

not_yet_recruiting110%

unknown110%

Recent Activity

0 active trials

Showing 5 of 10

completed

GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.

NCT04838743

withdrawn

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

NCT06113341

not_yet_recruitingphase_4

The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

NCT06408532

completedphase_3

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

NCT03862716

completedphase_3

IDegLira HIGH Trial

NCT03737240

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT04838743

GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.

Completed

NCT06113341

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

Withdrawn

NCT06408532Phase 4

The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

Not Yet Recruiting

NCT03862716Phase 3

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

IDegLira HIGH Trial

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

Completed

NCT05479591

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

Withdrawn

NCT05545800Phase 3

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

Unknown

NCT04190160Not Applicable

Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)

Completed

NCT04196231Phase 4

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Completed

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10